Cancer therapy with antibodies

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Cancer therapy faces challenges in selectively eliminating cancer cells while sparing normal tissues.
• Targeted therapies, particularly antibodies, offer improved specificity and therapeutic index over conventional treatments.
• Antibodies leverage high specificity to target antigens on cancer cells for therapeutic intervention.

Purpose of the Study:

• To review diverse therapeutic antibody strategies for cancer treatment.
• To elucidate the mechanisms of action, structural basis, and clinical applications of therapeutic antibodies.
• To discuss ongoing research aimed at enhancing efficacy and reducing toxicity of antibody-based cancer therapies.

Main Methods:

• Review of literature on therapeutic antibodies in cancer.
• Analysis of antibody mechanisms including direct antagonism, antibody-drug conjugates (ADCs), immune checkpoint inhibition, and bispecific antibodies.
• Discussion of structural aspects, clinical outcomes, and future research directions.

Main Results:

• Therapeutic antibodies employ various mechanisms to eradicate cancer cells, including direct targeting, payload delivery via ADCs, T-cell activation through immune checkpoint inhibition, and T-cell redirection by bispecific antibodies.
• Significant advancements have been made in antibody-based cancer therapies, leading to improved clinical outcomes.
• Ongoing research focuses on optimizing antibody design for greater efficacy and reduced side effects.

Conclusions:

• Therapeutic antibodies represent a powerful and evolving class of targeted cancer agents.
• Different antibody formats and mechanisms offer versatile strategies for cancer treatment.
• Continued innovation in antibody engineering and understanding of tumor immunology promises further advancements in oncology.